In osteoblastic MC3 T3-E1 cells exposed to different dosages of bortezomib, it has been demonstrated that TAZ inhibition in the MM milieu is essentially due to FGF-2 (fibroblast growth factor 2) [174]. Here, FGF2 is linked to Miyoshi myopathy.